CN1212150C - Medicine for treating virus hepatitis and its preparation method - Google Patents
Medicine for treating virus hepatitis and its preparation method Download PDFInfo
- Publication number
- CN1212150C CN1212150C CNB2003101039829A CN200310103982A CN1212150C CN 1212150 C CN1212150 C CN 1212150C CN B2003101039829 A CNB2003101039829 A CN B2003101039829A CN 200310103982 A CN200310103982 A CN 200310103982A CN 1212150 C CN1212150 C CN 1212150C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- powder
- standby
- viral hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title description 12
- 239000000843 powder Substances 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims description 36
- 201000001862 viral hepatitis Diseases 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 7
- -1 filter Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 241001534869 Terminalia Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 241000407170 Curcuma Species 0.000 description 3
- 235000014375 Curcuma Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 241001529553 Scoparia <angiosperm> Species 0.000 description 2
- 244000261559 Smilax china Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910002090 carbon oxide Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a method for preparing a medicament for treating virus hepatitis by using natural plant medicinal materials as main medicinal components. The medicament for treating virus hepatitis is prepared from raw materials of the following proportion by weight: 2 to 6 of bear gall powder, 10 to 25 of turmeric, 10 to 25 of gentian and 2 to 15 of medicine terminalia fruit. The medicament is convenient for administration and is developed by the Tibetan medicine theory prescription and the characteristics of the nature and the flavor of each medicine to extract effective components. The medicament is mainly used for treating virus hepatitis.
Description
Technical field
The present invention relates to a kind of with natural drug be main medicinal ingredient, have the medicine of treatment viral hepatitis effect and a preparation technology of this medicine thereof.
Technical background
Viral hepatitis is the common transmittable disease that is caused by multiple hepatitis virus, mainly show as weak, loss of appetite clinically, feel sick, vomiting, liver enlargement and liver function injury and characteristics such as infectiousness is strong, the course of disease is relatively long, hazardness is big, part patient can have jaundice and heating, inapparent infection is comparatively common, and viral hepatitis can be divided into five kinds on first type, B-mode, third type, fourth type and penta type.
China is the district occurred frequently of viral hepatitis.According to statistics, in Notifiable disease, its sickness rate occupies the 3rd, and hepatitis not only has a strong impact on follow-on health, and constitutes the threat to other many healthy persons, and therefore, the problem of preventing and treating of hepatitis has become the common important topic of paying close attention to of whole world medical circle.Since number century, the various countries scholar seeks best therapeutic scheme by different approach, wherein, seeks valuable clue from traditional medicine, increases treatment means and has become a kind of important channel of conquering viral hepatitis.The comprehensive study of Chinese medicine and ethnic drug preparation is to seek one of effective ways that solve viral hepatitis always.
Summary of the invention
The objective of the invention is to propose a kind of is the medicine of main medicinal ingredient and the treatment viral hepatitis with better curative effect with natural drug.
Another object of the present invention is to provide a kind of preparation method for the treatment of the viral hepatitis medicine.
Treatment viral hepatitis medicine of the present invention is the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15.
Treatment viral hepatitis medicine of the present invention is the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25.
Treatment viral hepatitis medicine of the present invention is the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25, Radix Et Rhizoma Rhei 2-15.
Treatment viral hepatitis medicine of the present invention is the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25, Radix Et Rhizoma Rhei 2-15, Herba Artemisiae Scopariae 10-25.
Treatment viral hepatitis medicine of the present invention is the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25, Radix Et Rhizoma Rhei 2-15, Herba Artemisiae Scopariae 10-25, Spica Prunellae 1-10.
Technical scheme of the present invention is based on Tibetanmedicine in the Chinese medicine to the understanding and the Therapeutic Principle of incidence of hepatitis mechanism, with reference to the modern pharmacology achievement in research, what filter out from motherland's medical treasure-house has clearing away heat-damp and promoting diuresis, a detoxifcation, the soothing liver-QI circulation of qi promoting, the natural medicinal plant of functions such as pain relieving, the present invention be one group according to the theoretical prescription of Tibetan medicine, and according to the nature and flavor characteristics of each herbal medicine, extract its active ingredient, the preparation of the taking convenience that develops.
Medicine of the present invention is mainly used in the treatment of viral hepatitis, comprises five kinds on first type, B-mode, third type, fourth type and penta type.
Pharmaceutical dosage form of the present invention is a said peroral dosage form on the pharmaceutics.Can be the capsule made through conventional technology of raw material of the present invention and corresponding medicinal adjuvant, tablet, granule, pill etc.Its consumption is per day for adults 2-6 gram.
The preparation method of treatment viral hepatitis medicine of the present invention is made up of following steps:
One, get Radix Gentianae by prescription and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, gets extractum;
Two, by prescription get the Fructus Chebulae, curcuma powder is broken into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
The preparation method of treatment viral hepatitis medicine of the present invention is made up of following steps:
One, get Radix Gentianae by prescription and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, gets extractum;
Two, get the Radix Aucklandiae, Fructus Chebulae, curcuma powder by prescription and be broken into fine powder, with the abundant mixing of aforementioned medicated powder, standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
The preparation method of treatment viral hepatitis medicine of the present invention is made up of following steps:
One, by prescription get Radix Et Rhizoma Rhei, Radix Gentianae decocts with water, and filters, and concentrates, and adds ethanol, use ethanol extraction, it is standby to get supernatant, must extractum;
Two, get the Radix Aucklandiae, Fructus Chebulae, curcuma powder by prescription and be broken into fine powder, with the abundant mixing of aforementioned medicated powder, standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
The preparation method of treatment viral hepatitis medicine of the present invention is made up of following steps:
One, get Radix Et Rhizoma Rhei, Herba Artemisiae Scopariae, Radix Gentianae by prescription and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, must extractum;
Two, get the Radix Aucklandiae, Rhizoma Curcumae Longae, Fructus Chebulae powder by prescription and be broken into fine powder, with the abundant mixing of aforementioned medicated powder, standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
The preparation method of treatment viral hepatitis medicine of the present invention is made up of following steps:
One, get Radix Et Rhizoma Rhei, Herba Artemisiae Scopariae, Radix Gentianae, Spica Prunellae by prescription and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, must extractum;
Two, get the Radix Aucklandiae, Rhizoma Curcumae Longae, Fructus Chebulae powder by prescription and be broken into fine powder, with the abundant mixing of aforementioned medicated powder, standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
In above-mentioned preparation method, used alcoholic acid volumetric concentration is 60-95%.
Pharmacodynamics test of the present invention:
Purpose: adopt young Mus immune organ weight method to observe this medicine to Immune Effects; Adopt CCl
4The hepatic injury mice is observed the hepatoprotective effect of this medicine; Cure mainly relevant drug action with reflection with this pharmic function.
One, this medicine is to Immune Effects
1, experiment material
Animal: mice, ICR, body weight 11-15g, male and female half and half are provided by Yunnan Province natural drug pharmacology key lab, the quality certification number: No. the 9806th, the real moving card in Yunnan.
Medicine: this medicine, the 0.5g/ grain is equivalent to crude drug in whole 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd., is made into 1.875%, 3.75% and 5.625% concentration confession usefulness with water.Radix Notoginseng total glucosides, Yunnan plant pharmaceutical factory product is made into 2.5% concentration for using with water.
2, experimental technique and result
Get 50 of mices, be divided into 5 groups at random, 10 every group, male and female half and half.If blank group (C), feedwater; The basic, normal, high dosage group of this medicine (L, M, H) is given this medicine medicinal liquid of 1.875%, 3.75% and 5.625% respectively; Positive controls (S) is given 2.5% Radix Notoginseng total glucosides medicinal liquid.Each group is all by 20ml/kg (ig) administration, and once a day, continuous 7 days, 24h did not pluck eyeball sacrificed by exsanguination mice after time administration, and extraction thymus and spleen are weighed, and calculate thymus and index and spleen index (mg/10g body weight).
3, conclusion
This medicine 0.75g/kg and 1.25g/kg all can make young Mus immune organ thymus index obviously rise (P＜0.05), show that this medicine has the effect of raise immunity.
Two, this medicine is to the effect of four carbonoxide hepatic injury
1, experiment material
Animal: mice, ICR, body weight 20-25g, male, provide the quality certification by Yunnan Province natural drug pharmacology key lab: No. the 9806th, the real moving card in Yunnan.
Medicine: this medicine, the 0.5g/ grain is equivalent to crude drug in whole 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd., is made into 1.875%, 3.75% and 5.625% concentration confession usefulness with water.YISHANLI JIAONANG, the 360mg/ grain, German Rhone-Poulenc Rorer product is made into 2.7% concentration for usefulness with water, four carbonoxides, the 500ml/ bottle, the Guangzhou Chemical Reagent Factory product, the concentration that is made into 0.1% (V/V) with Oleum Arachidis hypogaeae semen is for using.
Instrument: Kodak of Johnson ﹠ Johnson 750 type dry type biochemistry analyzer, the mutually beneficial company of U.S.-China.
Reagent: Kodak of Johnson ﹠ Johnson dry chemistry reagent, the mutually beneficial company of U.S.-China.
2, experimental technique and result
Get 60 of mices, be divided into 6 groups at random, 10 every group, establish normal control group (N), feedwater; Model control group (C); Feedwater; The basic, normal, high dosage group of this medicine (L, M, H) is given this medicine medicinal liquid of 1.875%, 3.75% and 5.625% respectively; Positive controls (S) is given 2.7% YISHANLI JIAONANG medicinal liquid.Each is organized all by 20ml/kg (ig) administration, once a day, and continuous 7 days.After time administration, N does not organize to NS10ml/kg (ig), and all the other 5 groups equal 0.1% (CCl4 Oleum Arachidis hypogaeae semen 10ml/kg (ip), behind the 16h, the eye socket rear vein beard is got blood and surveyed AST, ALT (enzyme process).
3, conclusion
After mice gives 0.1%CCl4 Oleum Arachidis hypogaeae semen 10ml/kg (ip); serum AST, ALT significantly raise (P＜0.001); show and cause the CCl4 liver injury model; and giving this medicine 0.75g/kg and 1.125g/kg all can make serum AST, ALT obviously descend (P＜0.01 and P＜0.001), this shows this medicine, and hepatic injury has protective effect to CCl4.
This medicine is to the long term toxicity test of rat:
This medicine is irritated stomach with 0.75g/kg, 2.25g/kg and 4.5g/kg dosage (being equivalent to 10 times, 30 times and 60 times with dosage of the clinical day for human beings according to the weight) and is given rat, once a day, continuous 45 days, big mouse cage look on examine no abnormal, body weight gain is normal, and hematology and blood biochemical are learned index main organs coefficient all in normal range.The high dose group rat heart, liver, spleen, lung, kidney, thyroid, thymus, adrenal gland, stomach and the histological examination of duodenum pathology show no obvious abnormalities.
The specific embodiment
Embodiment 1:
Get Radix Gentianae and decoct with water for 15 parts, use 60% ethanol extraction, left standstill 12 hours, it is standby to get supernatant; Other gets 20 parts in Rhizoma Curcumae Longae, the Fructus Chebulae is broken into fine powder for 10 parts, and with the abundant mixing of aforementioned medicated powder, drying is ground into fine powder again; To increase progressively mixing method with 4 parts of Fel Ursi powders and the abundant mixing of above-mentioned medicated powder, sterilization is made capsule according to the conventional tablet preparation method.
Embodiment 2:
Get Radix Gentianae and decoct with water for 20 parts, use 85% ethanol extraction, left standstill 24 hours, it is standby to get supernatant; Other gets 16 parts of the Radix Aucklandiae, 15 parts in Rhizoma Curcumae Longae, Fructus Chebulae and is broken into fine powder for 12 parts, and with the abundant mixing of aforementioned medicated powder, drying is ground into fine powder again; To increase progressively mixing method with 6 parts of Fel Ursi powders and the abundant mixing of above-mentioned medicated powder, sterilization is made capsule according to the conventional tablet preparation method.
Embodiment 3:
Get 8 parts of Radix Et Rhizoma Rhei, Radix Gentianae decocts with water for 18 parts, uses 70% ethanol extraction, leaves standstill 48 hours, it is standby to get supernatant; Other gets 20 parts of the Radix Aucklandiae, 18 parts in Rhizoma Curcumae Longae, Fructus Chebulae and is broken into fine powder for 8 parts, and with the abundant mixing of aforementioned medicated powder, drying is ground into fine powder again; To increase progressively mixing method with 3 parts of Fel Ursi powders and the abundant mixing of above-mentioned medicated powder, sterilization is made capsule according to the conventional tablet preparation method.
Embodiment 4:
Get 13 parts of Radix Et Rhizoma Rhei, 20 parts of Herba Artemisiae Scopariaes, Radix Gentianae and decoct with water for 25 parts, use 75% ethanol extraction, left standstill 36 hours, it is standby to get supernatant; Other gets 18 parts of the Radix Aucklandiae, 23 parts in Rhizoma Curcumae Longae, Fructus Chebulae and is broken into fine powder for 13 parts, and with the abundant mixing of aforementioned medicated powder, drying is ground into fine powder again; To increase progressively mixing method with 2 parts of Fel Ursi powders and the abundant mixing of above-mentioned medicated powder, sterilization is made capsule according to the conventional tablet preparation method.
Embodiment 5:
Get 13 parts of Radix Et Rhizoma Rhei, 20 parts of Herba Artemisiae Scopariaes, 25 parts of Radix Gentianae, Spica Prunellae and decoct with water for 5 parts, use 75% ethanol extraction, left standstill 30 hours, it is standby to get supernatant; Other gets 18 parts of the Radix Aucklandiae, 23 parts in Rhizoma Curcumae Longae, Fructus Chebulae and is ground into fine powder for 13 parts, and with the abundant mixing of aforementioned medicated powder, drying is ground into fine powder again; To increase progressively mixing method with 2 parts of Fel Ursi powders and the abundant mixing of above-mentioned medicated powder, sterilization is made capsule according to the conventional tablet preparation method.
Claims (4)
1, a kind of medicine for the treatment of viral hepatitis is characterized in that it being the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25, Radix Et Rhizoma Rhei 2-15, Herba Artemisiae Scopariae 10-25.
2, a kind of medicine for the treatment of viral hepatitis is characterized in that it being the medicament of being made by the following weight proportion raw material: Fel Ursi powder 2-6, Rhizoma Curcumae Longae 10-25, Radix Gentianae 10-25, Fructus Chebulae 2-15, Radix Aucklandiae 10-25, Radix Et Rhizoma Rhei 2-15, Herba Artemisiae Scopariae 10-25, Spica Prunellae 1-10.
3, according to the preparation method of the medicine of the described treatment viral hepatitis of claim 1, it is characterized in that forming by following steps:
One, get Radix Et Rhizoma Rhei, Herba Artemisiae Scopariae, Radix Gentianae and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, must extractum;
Two, get the Radix Aucklandiae, Rhizoma Curcumae Longae, Fructus Chebulae powder and be broken into fine powder, fully mixing is standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
4, according to the preparation method of the medicine of the described treatment viral hepatitis of claim 2, it is characterized in that forming by following steps:
One, get Radix Et Rhizoma Rhei, Herba Artemisiae Scopariae, Radix Gentianae, Spica Prunellae and decoct with water, filter, concentrate, add ethanol, use ethanol extraction, leave standstill, it is standby to get supernatant, must extractum;
Two, get the Radix Aucklandiae, Rhizoma Curcumae Longae, Fructus Chebulae powder and be broken into fine powder, fully mixing is standby;
Three, with the abundant mixing of () and (two), pulverize once more, add the Fel Ursi powder mix homogeneously to increase progressively mixing method, drying is pulverized, and makes required dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101039829A CN1212150C (en) | 2003-10-28 | 2003-10-28 | Medicine for treating virus hepatitis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101039829A CN1212150C (en) | 2003-10-28 | 2003-10-28 | Medicine for treating virus hepatitis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1517123A CN1517123A (en) | 2004-08-04 |
| CN1212150C true CN1212150C (en) | 2005-07-27 |
Family
ID=34304255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101039829A Expired - Lifetime CN1212150C (en) | 2003-10-28 | 2003-10-28 | Medicine for treating virus hepatitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1212150C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121404A1 (en) * | 2009-04-24 | 2010-10-28 | 黑龙江省中药材Gap研究中心 | Bear bile extract and preparation method and use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105126016A (en) * | 2015-08-25 | 2015-12-09 | 北京世纪合辉医药科技股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and preparation method of composition |
-
2003
- 2003-10-28 CN CNB2003101039829A patent/CN1212150C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121404A1 (en) * | 2009-04-24 | 2010-10-28 | 黑龙江省中药材Gap研究中心 | Bear bile extract and preparation method and use thereof |
| JP2012524728A (en) * | 2009-04-24 | 2012-10-18 | 黒竜江省中薬材Ｇａｐ研究中心 | Kumabori polymer extract and its preparation and use |
| US8753688B2 (en) | 2009-04-24 | 2014-06-17 | Heilongjiang Gap (Good Agriculture Practice) Research Center | Bear bile macromolecular extract and preparation method and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1517123A (en) | 2004-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1111046C (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1729992A (en) | External bath lotion for epidemic common cold due to wind-cold | |
| CN1682939A (en) | Medicine for treating virus hepatitis and preparing method | |
| CN1682814A (en) | Medicine for treating hepatitis B and its preparing process | |
| CN1292766C (en) | Chinese medicinal preparation for treating viral myocarditis and its making method | |
| CN1242767C (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1161132C (en) | Tibetan medicine for treating hepatism and its preparing process | |
| CN1186044C (en) | Chinese medicine 'lidandishi' for treating hepatobiliary calculus and cholecystitis | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1203891C (en) | Medicine for treating coronary heart disease and its preparation method | |
| CN1251745C (en) | Medicine for treating liver and biliary diseases and its preparing method | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1247222C (en) | Pharmaceutical composition for treating AlDS | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200814 Address after: 650200 Da Cun Xiao Changshan, osanqiao sub district office, Guandu District, Kunming City, Yunnan Province Patentee after: Yunnan Sunsail Pharmaceutical Co.,Ltd. Address before: 650011, Dongfeng East Road, Panlong District, Yunnan, Kunming 14 Patentee before: Wen Xianmin |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050727 |
|
| CX01 | Expiry of patent term |